NCT05040750

Brief Summary

By July 9, 2020, the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had resulted in over 11.8 million confirmed cases and over 545000 deaths. Patients with a history of cardiovascular disease are especially vulnerable and have a bad prognosis. According to the findings, cardiac injury manifested by cardiac biomarker elevation is detected in a significant number of COVID-19 patients and is linked to poor outcomes and mortality. However, it is unclear how effective cardiac biomarkers are in COVID-19 prognosis and how to use these indicators.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
207

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2021

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

September 9, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 10, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2023

Completed
Last Updated

October 8, 2024

Status Verified

October 1, 2024

Enrollment Period

1.9 years

First QC Date

September 9, 2021

Last Update Submit

October 7, 2024

Conditions

Cardiac Event

Outcome Measures

Primary Outcomes (1)

  • relation between cardiac markers and mortality rate in critically ill COVID 19 patients

    relate cardiac biomarkers to mortality rate

    4 month

Secondary Outcomes (1)

  • relation ship between cardiac and inflammatory and coagulation markers

    4 month

Study Arms (1)

moderate to severe COVID 19 patients

moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed

Other: laboratory investigation

Interventions

laboratory investigationOTHER

observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients

moderate to severe COVID 19 patients

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

all moderate to severe COVID 19 patients who were admitted to ICU

You may qualify if:

  • all moderate to severe COVID 19 patients who were admitted to ICU.
  • Both genders
  • age group 18-60 years

You may not qualify if:

  • a refusal to participate in the study,
  • pregnant patients,
  • patients aged \<18 or \>60. years,
  • recent history of acute myocardial infarction (\< 1 month before admission).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University

Cairo, 69711, Egypt

Location

MeSH Terms

Conditions

Cardiovascular Diseases

Study Officials

  • Fathy Tash, MD

    Ain Shams University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor of Anaesthesia

Study Record Dates

First Submitted

September 9, 2021

First Posted

September 10, 2021

Study Start

September 1, 2021

Primary Completion

July 30, 2023

Study Completion

July 30, 2023

Last Updated

October 8, 2024

Record last verified: 2024-10

Locations

EG(1)